Q-omics provides the consensus-scored BTNL2 profile across patient tissues and cancer cell-line models. BTNL2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BTNL2 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, BTNL2 RNA expression shows 13,824 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where BTNL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTNL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTNL2 survival associations across molecular data types. BTNL2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTNL2 RNA expression–survival associations across cancer types. High BTNL2 expression shows unfavorable associations in LIHC and LGG, but favorable associations in HNSC, UCS, ACC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BTNL2 RNA expression.
This table summarizes BTNL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BTNL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTNL2 shows lower tumor expression in KICH, UCEC, COAD, BRCA and STAD and higher tumor expression in HNSC. The KICH box plot shows higher BTNL2 RNA expression in normal versus tumor tissue (log2 FC = −0.290, t-test p < 0.001).
This table shows molecular features associated with BTNL2 in patient tissues and cancer cell lines. In patient samples, BTNL2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BTNL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
